PIK3CA and non-small cell lung carcinoma: Non-small cell lung cancer (NSCLC) accounts for about 85% of cases and includes adenocarcinomas, characterized by RAS or EGFR mutations, squamous cell carcinoma with FGFR1 amplification, PTEN or PIK3CA mutations [2,3], and large cell carcinoma, which are highly heterogeneous.